EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Cytokine release syndrome in solid tumors

David Synnott iD, David O'Reilly, Declan De Freitas, Jarushka Naidoo

Cancer · 01.09.2025 · 131 (17)

DOI: 10.1002/cncr.70069 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 23.08.2025. Verfasst von David Synnott und 3 weiteren Autor:innen. Beteiligte Einrichtung: Beaumont Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Neoplasms, Cytokine Release Syndrome, Immunotherapy. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytokine release syndrome (CRS) is a common and potentially severe complication of cancer immunotherapy, including CAR T‐cell therapies, bispecific T‐cell engagers, and less commonly immune checkpoint inhibitors. Although extensive research has established guidelines for managing CRS in hematological malignancies, there is a growing need to address CRS in the context of solid organ tumors due to differences in tumor microenvironment, immunotherapy indications, and patient population. This review aims to provide an overview of CRS in solid tumors, outlining its pathophysiology, clinical presentation, and current management strategies. The complexities of CRS in solid tumors arise from challenges such as the immunosuppressive nature of the tumor microenvironment and the overlap of tumor‐associated antigens with healthy tissues, potentially increasing the risk of severe on‐target off‐tumor toxicities. The review emphasizes early detection and grading of CRS as essential for patient safety and effective intervention. Management of CRS involves supportive care for mild cases, whereas severe presentations often require targeted therapies like tocilizumab, corticosteroids, and escalation to the intensive care unit for organ support. The decision to rechallenge or withhold immunotherapy requires careful consideration of patient‐specific goals and risks. Emerging treatments such as other cytokine inhibitors, plasma exchange, and suicide gene systems are promising avenues for mitigating severe CRS. Future research focuses on refining risk stratification tools, novel therapeutic agents, and evaluating long‐term outcomes. A deeper understanding of CRS in solid tumors will enable more personalized treatment approaches, enhancing the safety and efficacy of immunotherapies for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCytokine Release SyndromeImmunotherapyHumansTumor MicroenvironmentImmunotherapy, Adoptive

Stichwörter der Autor:innen

adoptivechimeric antigen receptor therapycytokine release syndromedrug‐related side effects and adverse reactionsimmune checkpoint inhibitorsimmunotherapysolid tumors

Autor:innen und Institutionen

  • Beaumont Hospital, Dublin, Ireland.
  • Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland.
  • Beaumont RCSI Cancer Centre, Dublin, Ireland.
  • RCSI University of Health Sciences, RCSI Cancer Centre, Dublin, Ireland.

ORCID-Profile: David Synnott

Zitieren

APA

Synnott, D., O'Reilly, D., De Freitas, D., & Naidoo, J. (2025). Cytokine release syndrome in solid tumors. Cancer, 131(17). https://doi.org/10.1002/cncr.70069

Vancouver

Synnott D, O'Reilly D, De Freitas D, Naidoo J. Cytokine release syndrome in solid tumors. Cancer. 2025;131(17). doi:10.1002/cncr.70069

BibTeX
@article{Synnott2025,
  author = {Synnott, David and O'Reilly, David and De Freitas, Declan and Naidoo, Jarushka},
  title = {Cytokine release syndrome in solid tumors},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {17},
  doi = {10.1002/cncr.70069}
}
Kostenlos starten →